- 8/3/2023 9:32:00 AM | 訪問量:3157
天勤生物助力金諾賽一類新藥金線蓮苷獲臨床批件
2023年7月28日,由武(wu)漢市金諾賽(sai)生物科技有限公司提交的一類新藥(yao)金線(xian)蓮苷片(pian)獲國家藥(yao)品監督管理局公示的臨(lin)床試驗默示許可,適(shi)應癥為治療非酒(jiu)精性脂(zhi)肪肝(gan)炎。
湖北天勤生物(wu)科技有限公司安評(ping)中心(xin)作為“金線蓮苷(gan)片”項(xiang)目的合(he)作伙伴,針對金線蓮苷(gan)的藥物(wu)特點與申報要(yao)求(qiu)開展(zhan)了全套毒理(li)試驗。

金線(xian)蓮苷(gan)一類新藥(yao)由華(hua)中科技大(da)學(xue)同濟(ji)醫學(xue)院藥(yao)學(xue)院院長(chang)張勇慧教授團隊(dui)負責研(yan)發(fa),具有完全自主(zhu)(zhu)知識產(chan)(chan)權(quan),系統性研(yan)究獲得的相關10項專利包(bao)括1項美國授權(quan)專利已實現成(cheng)果轉化。金線(xian)蓮產(chan)(chan)業(ye)目前主(zhu)(zhu)要以農(nong)業(ye)種植和原料初(chu)加工為主(zhu)(zhu),金線(xian)蓮苷(gan)一類護肝新藥(yao)的開發(fa),將產(chan)(chan)生巨大(da)的社會(hui)效益和經濟(ji)效益。
天(tian)勤(qin)生(sheng)物祝(zhu)賀金(jin)線(xian)蓮(lian)苷片順利獲(huo)批臨床,祝(zhu)愿金(jin)線(xian)蓮(lian)苷可以早日獲(huo)批上市,以更好的療效造福國內外肝病者。同時,天(tian)勤(qin)生(sheng)物將不斷探索和積累相關試驗(yan)技術,提(ti)升服務能力,以期為全球更多客(ke)戶提(ti)供(gong)優(you)質高(gao)效的服務,助力新藥快速獲(huo)批!
- 天勤生物聯合多家企業榮獲湖北省科學技術進步二等獎
- 2025-09-03
近日,2025年度(du)(du)(du)湖(hu)北(bei)(bei)省(sheng)科學技(ji)術(shu)(shu)進步獎名單公示(shi),由天(tian)勤生物(wu)(wu)聯合湖(hu)北(bei)(bei)省(sheng)醫(yi)(yi)藥(yao)(yao)(yao)(yao)工(gong)業研究(jiu)院(yuan)有(you)(you)限(xian)(xian)(xian)公司、湖(hu)北(bei)(bei)麗益醫(yi)(yi)藥(yao)(yao)(yao)(yao)科技(ji)有(you)(you)限(xian)(xian)(xian)公司、湖(hu)北(bei)(bei)科益藥(yao)(yao)(yao)(yao)業股份有(you)(you)限(xian)(xian)(xian)公司、武(wu)漢(han)福星(xing)生物(wu)(wu)藥(yao)(yao)(yao)(yao)業有(you)(you)限(xian)(xian)(xian)公司共同完成的(de)(de)“湖(hu)北(bei)(bei)道(dao)地(di)與(yu)(yu)特色(se)藥(yao)(yao)(yao)(yao)材藥(yao)(yao)(yao)(yao)用(yong)(yong)(yong)價值的(de)(de)深度(du)(du)(du)挖掘及(ji)其(qi)應(ying)用(yong)(yong)(yong)”項(xiang)目(mu),榮(rong)獲二(er)等獎。這一(yi)成果標志著湖(hu)北(bei)(bei)省(sheng)在(zai)道(dao)地(di)藥(yao)(yao)(yao)(yao)材資源(yuan)開(kai)發利用(yong)(yong)(yong)與(yu)(yu)中(zhong)(zhong)醫(yi)(yi)藥(yao)(yao)(yao)(yao)現(xian)(xian)代化研究(jiu)方面(mian)取得重(zhong)要進展。 該(gai)項(xiang)目(mu)系(xi)(xi)統(tong)針對(dui)湖(hu)北(bei)(bei)省(sheng)道(dao)地(di)藥(yao)(yao)(yao)(yao)材及(ji)特色(se)藥(yao)(yao)(yao)(yao)用(yong)(yong)(yong)資源(yuan),在(zai)活性成分提(ti)(ti)取、藥(yao)(yao)(yao)(yao)理機制探(tan)索以(yi)及(ji)現(xian)(xian)代藥(yao)(yao)(yao)(yao)物(wu)(wu)研發等方面(mian),開(kai)展從基礎研究(jiu)到產(chan)業應(ying)用(yong)(yong)(yong)的(de)(de)全鏈(lian)條協同攻關(guan)。湖(hu)北(bei)(bei)省(sheng)作為(wei)中(zhong)(zhong)醫(yi)(yi)藥(yao)(yao)(yao)(yao)資源(yuan)大省(sheng),素(su)有(you)(you)“華中(zhong)(zhong)藥(yao)(yao)(yao)(yao)庫”之(zhi)美譽,但藥(yao)(yao)(yao)(yao)材資源(yuan)的(de)(de)深度(du)(du)(du)開(kai)發和(he)(he)現(xian)(xian)代化應(ying)用(yong)(yong)(yong)仍面(mian)臨一(yi)定的(de)(de)局限(xian)(xian)(xian)。該(gai)項(xiang)目(mu)不僅提(ti)(ti)升了(le)湖(hu)北(bei)(bei)道(dao)地(di)藥(yao)(yao)(yao)(yao)材的(de)(de)應(ying)用(yong)(yong)(yong)水平,也為(wei)區域性中(zhong)(zhong)藥(yao)(yao)(yao)(yao)產(chan)業提(ti)(ti)質增效和(he)(he)結構(gou)升級(ji)提(ti)(ti)供(gong)了(le)技(ji)術(shu)(shu)支(zhi)撐。天(tian)勤生物(wu)(wu)作為(wei)項(xiang)目(mu)參(can)與(yu)(yu)方之(zhi)一(yi),在(zai)藥(yao)(yao)(yao)(yao)物(wu)(wu)藥(yao)(yao)(yao)(yao)理與(yu)(yu)毒(du)理研究(jiu)、成藥(yao)(yao)(yao)(yao)性評價等領域發揮(hui)了(le)重(zhong)要作用(yong)(yong)(yong)。 這一(yi)獎項(xiang)的(de)(de)獲得,不僅是(shi)對(dui)項(xiang)目(mu)組創新實踐的(de)(de)高(gao)度(du)(du)(du)認可,更將(jiang)進一(yi)步推動湖(hu)北(bei)(bei)省(sheng)中(zhong)(zhong)醫(yi)(yi)藥(yao)(yao)(yao)(yao)資源(yuan)的(de)(de)系(xi)(xi)統(tong)性挖掘與(yu)(yu)價值轉化。未來,相關(guan)技(ji)術(shu)(shu)成果有(you)(you)望(wang)在(zai)更多道(dao)地(di)藥(yao)(yao)(yao)(yao)材研究(jiu)中(zhong)(zhong)推廣(guang)應(ying)用(yong)(yong)(yong),為(wei)中(zhong)(zhong)醫(yi)(yi)藥(yao)(yao)(yao)(yao)現(xian)(xian)代化和(he)(he)產(chan)業高(gao)質量發展持(chi)續注入新動能。
- 天勤生物助力人福醫藥IPF新藥HW241045片獲批臨床
- 2025-08-12
近日,國(guo)家藥(yao)品監(jian)督管(guan)理局(ju)藥(yao)品審(shen)評中心(CDE)官網(wang)公(gong)示,人福(fu)(fu)醫藥(yao)集團申(shen)(shen)報(bao)(bao)的(de)(de)1類創(chuang)(chuang)新藥(yao)HW241045片(pian)正式獲得國(guo)家藥(yao)品監(jian)督管(guan)理局(ju)頒發的(de)(de)《藥(yao)物臨床試驗批(pi)準(zhun)通知書(shu)》,擬用于治(zhi)(zhi)療特發性(xing)肺纖維化(hua)(IPF)。在這(zhe)一(yi)重大進(jin)(jin)展(zhan)背后(hou),天(tian)勤生物提(ti)供的(de)(de)全方(fang)(fang)位毒(du)(du)理學研(yan)究(jiu)(jiu)(jiu)支持,為該(gai)項目獲批(pi)按下(xia)"加速鍵(jian)"。聚焦未滿足臨床需求(qiu),HW241045片(pian)引領(ling)呼吸領(ling)域創(chuang)(chuang)新突(tu)破HW241045片(pian)作(zuo)為人福(fu)(fu)醫藥(yao)重點(dian)布局(ju)的(de)(de)1類創(chuang)(chuang)新藥(yao),聚焦臨床需求(qiu)迫切的(de)(de)IPF領(ling)域。IPF作(zuo)為一(yi)種進(jin)(jin)行性(xing)肺部疾病,患(huan)者(zhe)預(yu)后(hou)差,現有(you)治(zhi)(zhi)療選擇(ze)有(you)限(xian)。HW241045片(pian)的(de)(de)研(yan)發進(jin)(jin)展(zhan),為患(huan)者(zhe)帶來了(le)(le)(le)新的(de)(de)希望曙光(guang)。科學把控,天(tian)勤生物毒(du)(du)理研(yan)究(jiu)(jiu)(jiu)助(zhu)力HW241045片(pian)加速獲批(pi)針對HW241045片(pian)的(de)(de)非臨床毒(du)(du)理研(yan)究(jiu)(jiu)(jiu),天(tian)勤生物展(zhan)現了(le)(le)(le)成熟的(de)(de)試驗設計與(yu)執行能力。從試驗方(fang)(fang)案(an)的(de)(de)科學論(lun)證(zheng)到試驗過(guo)程(cheng)的(de)(de)精細化(hua)管(guan)理,團隊通過(guo)標(biao)準(zhun)化(hua)操作(zuo)流程(cheng)和動態風險評估(gu)機制,有(you)效(xiao)確(que)保了(le)(le)(le)數據可靠性(xing)與(yu)合(he)規性(xing)。其(qi)對項目節奏的(de)(de)科學化(hua)把控也(ye)為人福(fu)(fu)醫藥(yao)搶抓臨床申(shen)(shen)報(bao)(bao)提(ti)供了(le)(le)(le)關鍵(jian)支持,保障了(le)(le)(le)該(gai)項目順(shun)利(li)通過(guo)審(shen)評。此次與(yu)人福(fu)(fu)醫藥(yao)的(de)(de)成功(gong)合(he)作(zuo),也(ye)印證(zheng)了(le)(le)(le)天(tian)勤生物作(zuo)的(de)(de)專業價值。其(qi)系(xi)統化(hua)的(de)(de)技術(shu)平臺(tai)與(yu)嚴(yan)謹高效(xiao)的(de)(de)研(yan)究(jiu)(jiu)(jiu)服(fu)務,正日益成為本土創(chuang)(chuang)新藥(yao)企(qi)加...
- 天勤生物攜手睿智醫藥,共筑從靶點到IND一站式新藥研發平臺
- 2025-07-29
近(jin)日,天(tian)勤(qin)生(sheng)物(wu)(wu)與睿智(zhi)醫藥(yao)(yao)(yao)(yao)(yao)科技股份有(you)限公(gong)司(以下稱“睿智(zhi)醫藥(yao)(yao)(yao)(yao)(yao)”)正式簽署戰略合作(zuo)(zuo)協議。此次(ci)合作(zuo)(zuo)旨在(zai)(zai)(zai)深度融合雙(shuang)方在(zai)(zai)(zai)創(chuang)新(xin)藥(yao)(yao)(yao)(yao)(yao)研(yan)發(fa)(fa)產業鏈(lian)上的(de)(de)(de)(de)(de)核(he)心優勢(shi)(shi),共同(tong)打造覆(fu)蓋“從靶(ba)(ba)點(dian)(dian)發(fa)(fa)現至IND”全(quan)(quan)流(liu)程的(de)(de)(de)(de)(de)一站式服務平臺(tai),為(wei)(wei)全(quan)(quan)球藥(yao)(yao)(yao)(yao)(yao)企(qi)提供更(geng)高效、更(geng)專(zhuan)業的(de)(de)(de)(de)(de)解決(jue)方案。 睿智(zhi)醫藥(yao)(yao)(yao)(yao)(yao)作(zuo)(zuo)為(wei)(wei)國(guo)內(nei)臨床前(qian)CRO領域(yu)的(de)(de)(de)(de)(de)佼佼者(zhe),自2004年成立以來,已構建(jian)起(qi)從抗體及(ji)化藥(yao)(yao)(yao)(yao)(yao)早(zao)(zao)期(qi)(qi)研(yan)發(fa)(fa)、藥(yao)(yao)(yao)(yao)(yao)理(li)藥(yao)(yao)(yao)(yao)(yao)效、藥(yao)(yao)(yao)(yao)(yao)代動力(li)學(xue)到(dao)早(zao)(zao)期(qi)(qi)毒理(li)研(yan)究(jiu)(jiu)、生(sheng)物(wu)(wu)分(fen)析(xi)乃(nai)至生(sheng)物(wu)(wu)藥(yao)(yao)(yao)(yao)(yao)工(gong)藝開(kai)發(fa)(fa)與生(sheng)產的(de)(de)(de)(de)(de)全(quan)(quan)鏈(lian)條能(neng)力(li),尤其(qi)在(zai)(zai)(zai)靶(ba)(ba)點(dian)(dian)驗證到(dao)IND申報的(de)(de)(de)(de)(de)早(zao)(zao)期(qi)(qi)創(chuang)新(xin)階段具備強大實(shi)力(li)。 天(tian)勤(qin)生(sheng)物(wu)(wu)在(zai)(zai)(zai)創(chuang)新(xin)藥(yao)(yao)(yao)(yao)(yao)物(wu)(wu)臨床前(qian)安全(quan)(quan)性評(ping)價領域(yu)擁有(you)深厚積累,特別是(shi)在(zai)(zai)(zai)大分(fen)子治(zhi)(zhi)療性藥(yao)(yao)(yao)(yao)(yao)物(wu)(wu)、細胞(bao)與基(ji)因治(zhi)(zhi)療產品(pin)等領域(yu)的(de)(de)(de)(de)(de)研(yan)究(jiu)(jiu)有(you)獨特優勢(shi)(shi),在(zai)(zai)(zai)非人靈(ling)長(chang)類動物(wu)(wu)模型構建(jian)與藥(yao)(yao)(yao)(yao)(yao)效評(ping)價及(ji)猴生(sheng)殖與發(fa)(fa)育毒性方面(mian)(mian)也能(neng)力(li)突出,其(qi)服務全(quan)(quan)面(mian)(mian)覆(fu)蓋藥(yao)(yao)(yao)(yao)(yao)物(wu)(wu)毒理(li)安全(quan)(quan)性評(ping)價、藥(yao)(yao)(yao)(yao)(yao)代藥(yao)(yao)(yao)(yao)(yao)效研(yan)究(jiu)(jiu)、生(sheng)物(wu)(wu)分(fen)析(xi)及(ji)大動物(wu)(wu)模型開(kai)發(fa)(fa)等關鍵(jian)環(huan)節(jie)。 此次(ci)合作(zuo)(zuo),天(tian)勤(qin)生(sheng)物(wu)(wu)和睿智(zhi)醫藥(yao)(yao)(yao)(yao)(yao)將精準(zhun)契合創(chuang)新(xin)藥(yao)(yao)(yao)(yao)(yao)研(yan)發(fa)(fa)產業鏈(lian)的(de)(de)(de)(de)(de)各自優勢(shi)(shi)環(huan)節(jie),形(xing)成資源(yuan)互補、聯合攻關的(de)(de)(de)(de)(de)強大合力(li),并在(zai)(zai)(zai)此基(ji)礎上緊(jin)密協作(zuo)(zuo),共同(tong)組建(jian)“從靶(ba)(ba)點(dian)(dian)到(dao)IND的(de)(de)(de)(de)(de)一站式新(xin)藥(yao)(yao)(yao)(yao)(yao)研(yan)發(fa)(fa)平臺(tai)”。該平臺(tai)將致力(li)于為(wei)(wei)客(ke)戶提供更(geng)全(quan)(quan)面(mian)(mian)、更(geng)具創(chuang)...
- 天勤生物榮膺CGT領域最佳CRO合作伙伴啟明星獎
- 2025-06-09
在(zai)(zai)第(di)六屆國際細胞(bao)與(yu)基因治療中(zhong)國峰會(hui)暨展(zhan)覽會(hui)(CGCS 2025)現場(chang),備受矚目的(de)(de)(de)(de)(de)CGCS Awards啟(qi)(qi)明星(xing)(xing)獎項(xiang)隆重揭曉。天勤(qin)生(sheng)物憑借其(qi)在(zai)(zai)細胞(bao)與(yu)基因治療(CGT)非(fei)臨床研(yan)(yan)究(jiu)(jiu)(jiu)領域的(de)(de)(de)(de)(de)突出(chu)貢獻,從(cong)眾多競爭者中(zhong)脫(tuo)穎而出(chu),榮膺 “CGT領域最(zui)佳CRO合(he)(he)作(zuo)(zuo)伙伴啟(qi)(qi)明星(xing)(xing)獎”。這一(yi)殊榮是CGCS組(zu)委會(hui)及行(xing)業權(quan)威專家對天勤(qin)生(sheng)物在(zai)(zai)該領域核(he)心(xin)價值的(de)(de)(de)(de)(de)高(gao)度肯(ken)定。 CGCS Awards啟(qi)(qi)明星(xing)(xing)獎評(ping)選(xuan)(xuan)活動由(you)CGCS組(zu)委會(hui)權(quan)威發起,評(ping)選(xuan)(xuan)過程嚴謹(jin)公(gong)正,融合(he)(he)了(le)組(zu)委會(hui)資深專家評(ping)審(shen)團的(de)(de)(de)(de)(de)深度評(ping)議與(yu)廣泛網絡投票。評(ping)審(shen)維度覆蓋技(ji)術實(shi)用(yong)性(xing)與(yu)創(chuang)新性(xing)、市場(chang)表現、客戶(hu)服務口(kou)碑(bei)、未來發展(zhan)潛力(li)等多個核(he)心(xin)指標。天勤(qin)生(sheng)物以其(qi)深厚的(de)(de)(de)(de)(de)技(ji)術積累、可靠的(de)(de)(de)(de)(de)服務質(zhi)量以及來自合(he)(he)作(zuo)(zuo)伙伴的(de)(de)(de)(de)(de)廣泛贊譽,在(zai)(zai)綜合(he)(he)評(ping)選(xuan)(xuan)中(zhong)實(shi)力(li)勝出(chu)。 此次獲獎,不(bu)僅彰顯(xian)了(le)天勤(qin)生(sheng)物在(zai)(zai)CGT非(fei)臨床研(yan)(yan)究(jiu)(jiu)(jiu)服務鏈條中(zhong)作(zuo)(zuo)為關鍵支撐者與(yu)可信賴伙伴的(de)(de)(de)(de)(de)核(he)心(xin)地位,更是業界對其(qi)賦能創(chuang)新療法安全高(gao)效(xiao)開發所發揮作(zuo)(zuo)用(yong)的(de)(de)(de)(de)(de)廣泛認可。天勤(qin)生(sheng)物始終致力(li)于打造專業高(gao)效(xiao)的(de)(de)(de)(de)(de)CRO服務平(ping)臺(tai),其(qi)科(ke)學嚴謹(jin)的(de)(de)(de)(de)(de)研(yan)(yan)究(jiu)(jiu)(jiu)體系與(yu)解決方案,已(yi)成為加(jia)速(su)CGT產品從(cong)實(shi)驗室走向臨床、惠及患(huan)者的(de)(de)(de)(de)(de)重要保障。 天勤(qin)生(sheng)物將繼續深化在(zai)(zai)CG...
- 天勤生物受邀出席同濟醫院綜合類國家醫學中心科創院理事會成立大會
- 2025-06-05
6月(yue)4日上午,同(tong)(tong)(tong)(tong)濟醫(yi)(yi)院(yuan)(yuan)(yuan)綜合類國(guo)家醫(yi)(yi)學(xue)(xue)(xue)中(zhong)心(xin)(籌)科創(chuang)院(yuan)(yuan)(yuan)理(li)事(shi)會(hui)(hui)成(cheng)立大(da)會(hui)(hui)在武漢同(tong)(tong)(tong)(tong)濟產(chan)(chan)(chan)業(ye)(ye)科創(chuang)中(zhong)心(xin)隆重(zhong)舉行。作為同(tong)(tong)(tong)(tong)濟醫(yi)(yi)院(yuan)(yuan)(yuan)重(zhong)要的(de)(de)戰(zhan)略合作伙伴,天(tian)勤(qin)生(sheng)物(wu)受邀出席盛會(hui)(hui),與各界代表(biao)共(gong)繪醫(yi)(yi)學(xue)(xue)(xue)創(chuang)新(xin)(xin)藍(lan)圖。 本(ben)次(ci)大(da)會(hui)(hui)規格(ge)隆重(zhong),由同(tong)(tong)(tong)(tong)濟醫(yi)(yi)院(yuan)(yuan)(yuan)常務副院(yuan)(yuan)(yuan)長(chang)、科創(chuang)院(yuan)(yuan)(yuan)理(li)事(shi)會(hui)(hui)常務副理(li)事(shi)長(chang)廖家智主持。湖北省、武漢市及硚口(kou)區相關部門(men)領(ling)導,同(tong)(tong)(tong)(tong)濟醫(yi)(yi)院(yuan)(yuan)(yuan)及科創(chuang)院(yuan)(yuan)(yuan)負(fu)責人(ren),中(zhong)國(guo)工程(cheng)(cheng)院(yuan)(yuan)(yuan)院(yuan)(yuan)(yuan)士(shi)馬丁等領(ling)導專(zhuan)家出席。來自40家國(guo)內外(wai)頂尖醫(yi)(yi)療(liao)企業(ye)(ye)的(de)(de)百余名(ming)代表(biao)參會(hui)(hui),共(gong)同(tong)(tong)(tong)(tong)見證。 天(tian)勤(qin)生(sheng)物(wu)作為與會(hui)(hui)方(fang),其與同(tong)(tong)(tong)(tong)濟醫(yi)(yi)院(yuan)(yuan)(yuan)的(de)(de)戰(zhan)略合作,正是響應大(da)會(hui)(hui)倡導的(de)(de)“產(chan)(chan)(chan)學(xue)(xue)(xue)研深度(du)融合”方(fang)向(xiang)。雙方(fang)致力(li)(li)于整合同(tong)(tong)(tong)(tong)濟醫(yi)(yi)院(yuan)(yuan)(yuan)在科技研發(fa)、高端人(ren)才資源與卓越(yue)醫(yi)(yi)學(xue)(xue)(xue)教(jiao)育方(fang)面的(de)(de)深厚(hou)積淀,以及天(tian)勤(qin)生(sheng)物(wu)在非(fei)人(ren)靈長(chang)類實(shi)驗動物(wu)模型開發(fa)、高標準新(xin)(xin)藥非(fei)臨床研究(jiu)服務、先進大(da)動物(wu)分子(zi)影(ying)像檢(jian)測(ce)平臺等領(ling)域的(de)(de)核心(xin)優勢。此次(ci)合作以具體項目為紐帶,旨在構(gou)建(jian)(jian)“產(chan)(chan)(chan)學(xue)(xue)(xue)研用”一體化創(chuang)新(xin)(xin)鏈條,加速科研成(cheng)果向(xiang)臨床治療(liao)應用的(de)(de)轉化進程(cheng)(cheng),最終惠(hui)及人(ren)民健康福祉,實(shi)現優勢互補(bu)、互惠(hui)雙贏。 天(tian)勤(qin)生(sheng)物(wu)期(qi)待與同(tong)(tong)(tong)(tong)濟醫(yi)(yi)院(yuan)(yuan)(yuan)攜手,逐步構(gou)建(jian)(jian)起一個(ge)運轉高效、充滿活(huo)力(li)(li)的(de)(de)產(chan)(chan)(chan)學(xue)(xue)(xue)研協同(tong)(tong)(tong)(tong)創(chuang)新(xin)(xin)體系,共(gong)同(tong)(tong)(tong)(tong)打造跨地域、跨領(ling)域協同(tong)(tong)(tong)(tong)創(chuang)新(xin)(xin)高質量發(fa)展的(de)(de)...






新聞動態


